^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

murlentamab (GM102)

i
Other names: GM102, GM 102, 3C23K
Company:
Exelixis
Drug class:
AMHR2 antagonist
11ms
Anti-Müllerian hormone - clinical use and future possibilities. (PubMed, Ceska Gynekol)
In oncology, it is used as a tumor marker for monitoring patients with granulosa tumors. In the future, however, it is also promising to use the knowledge of AMH function for the treatment of gynecological as well as other solid malignancies expressing a tissue-specific receptor for AMH.
Journal
|
murlentamab (GM102)
almost3years
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. (PubMed, Biology (Basel))
Overall, our results suggest that this embryonic receptor could be a suitable target for treating AMHRII-expressing tumors with an anti-AMHRII selective agent such as murlentamab, also named 3C23K or GM102. This potential therapeutic intervention was confirmed in vivo by showing antitumor activity of murlentamab against AMHRII-expressing colorectal cancer and hepatocarcinoma Patient-Derived tumor Xenografts (PDX) models.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
murlentamab (GM102)
almost3years
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. (PubMed, Cancers (Basel))
Those mechanisms might contribute to the sustained clinical benefit observed in advanced cancer patients treated with murlentamab. Finally, the enhanced murlentamab activity in combination with pembrolizumab opens new therapeutic perspectives.
Journal • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • murlentamab (GM102)
almost4years
Circulating CD14 CD16 intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. (PubMed, J Immunother Cancer)
This study, which links IBM level with immunosuppression and tumor burden in peritoneum, identifies IBMs as apotential predictive signature of ascites immune status and as a biomarker ofovarian cancer development and treatment response.
Journal
|
CD163 (CD163 Molecule) • CD14 (CD14 Molecule)
|
murlentamab (GM102)